Benefits of nonionic contrast in coronary arteriography: Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76

Allen A. Ciuffo, Richard M. Fuchs, Pablo A. Guzman, Kenneth P. Brin, Dean E. Kross, James L Weiss, Robin W. Feroli, Jeffrey A Brinker

Research output: Contribution to journalArticle

Abstract

The cardiovascular effects of the commonly used ionic contrast, 76% sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4% versus 13%) P <0.001, heart rate (4% versus 26%) P <0.01, and left ventricular contractility, P <0.03, than Renografin-76. In addition, intracoronary iopamidol prolonged the QT interval less (23% versus 2%)P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60% versus 153%) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.

Original languageEnglish (US)
Pages (from-to)S197-S202
JournalInvestigative Radiology
Volume19
Issue number5
StatePublished - 1984

Fingerprint

Iopamidol
Angiography
Contrast Media
Diatrizoate Meglumine
Diatrizoate
Double-Blind Method
Cross-Over Studies
Heart Rate
Blood Pressure
Injections
urovision

Keywords

  • Contrast toxicity
  • Coronary arteriography
  • Iopamidol
  • Renografin-76

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Benefits of nonionic contrast in coronary arteriography : Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76. / Ciuffo, Allen A.; Fuchs, Richard M.; Guzman, Pablo A.; Brin, Kenneth P.; Kross, Dean E.; Weiss, James L; Feroli, Robin W.; Brinker, Jeffrey A.

In: Investigative Radiology, Vol. 19, No. 5, 1984, p. S197-S202.

Research output: Contribution to journalArticle

Ciuffo, Allen A. ; Fuchs, Richard M. ; Guzman, Pablo A. ; Brin, Kenneth P. ; Kross, Dean E. ; Weiss, James L ; Feroli, Robin W. ; Brinker, Jeffrey A. / Benefits of nonionic contrast in coronary arteriography : Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76. In: Investigative Radiology. 1984 ; Vol. 19, No. 5. pp. S197-S202.
@article{2770b97867ca4e4bb1919f3c90642137,
title = "Benefits of nonionic contrast in coronary arteriography: Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76",
abstract = "The cardiovascular effects of the commonly used ionic contrast, 76{\%} sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4{\%} versus 13{\%}) P <0.001, heart rate (4{\%} versus 26{\%}) P <0.01, and left ventricular contractility, P <0.03, than Renografin-76. In addition, intracoronary iopamidol prolonged the QT interval less (23{\%} versus 2{\%})P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60{\%} versus 153{\%}) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.",
keywords = "Contrast toxicity, Coronary arteriography, Iopamidol, Renografin-76",
author = "Ciuffo, {Allen A.} and Fuchs, {Richard M.} and Guzman, {Pablo A.} and Brin, {Kenneth P.} and Kross, {Dean E.} and Weiss, {James L} and Feroli, {Robin W.} and Brinker, {Jeffrey A}",
year = "1984",
language = "English (US)",
volume = "19",
pages = "S197--S202",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Benefits of nonionic contrast in coronary arteriography

T2 - Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76

AU - Ciuffo, Allen A.

AU - Fuchs, Richard M.

AU - Guzman, Pablo A.

AU - Brin, Kenneth P.

AU - Kross, Dean E.

AU - Weiss, James L

AU - Feroli, Robin W.

AU - Brinker, Jeffrey A

PY - 1984

Y1 - 1984

N2 - The cardiovascular effects of the commonly used ionic contrast, 76% sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4% versus 13%) P <0.001, heart rate (4% versus 26%) P <0.01, and left ventricular contractility, P <0.03, than Renografin-76. In addition, intracoronary iopamidol prolonged the QT interval less (23% versus 2%)P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60% versus 153%) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.

AB - The cardiovascular effects of the commonly used ionic contrast, 76% sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4% versus 13%) P <0.001, heart rate (4% versus 26%) P <0.01, and left ventricular contractility, P <0.03, than Renografin-76. In addition, intracoronary iopamidol prolonged the QT interval less (23% versus 2%)P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60% versus 153%) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.

KW - Contrast toxicity

KW - Coronary arteriography

KW - Iopamidol

KW - Renografin-76

UR - http://www.scopus.com/inward/record.url?scp=0021144297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021144297&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0021144297

VL - 19

SP - S197-S202

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 5

ER -